Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy

NCT02020941 is registered in ClinicalTrials.gov with Attaya Suvannasankha as lead sponsor.

NCT NCT02020941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02020941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy
Lead sponsor
Attaya Suvannasankha
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2013
Completion date
April 30, 2016
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma